An Official Website of the United States Government
Company Information:
Name:
HOUSEY PHARMACEUTICAL RESEARCH LAB
Address:
16800 W 12 MILE RD, STE 201
SOUTHFIELD, MI 48076-
SOUTHFIELD, MI 48076-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Discovery and development of Antidiabetic Drugs
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Gerard M. Housey
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR application entitled "Discovery and Development of Antidiabetic Drugs," proposes to establish assay systems to identify and validate small molecules that promote the function of the insulin receptor substrate 2 (IRS2) in mammalian cells. IRS2… More
Discovery and Development of Antidiabetic Drugs
Award Year / Program / Phase:
2006 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Gerard M. Housey
Award Amount:
$852,467.00
Abstract:
DESCRIPTION (provided by applicant): This is the Phase 2 application entitled "Discovery and Development of Antidiabetic Drugs." The goal is to identify new molecular entities that promote the IRS2-branch of the insulin/IGF signaling system. The NIH support will be used to identify compounds that… More
Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Gerard M. Housey
Award Amount:
$149,616.00
Abstract:
DESCRIPTION (provided by applicant): This is the Phase 1 application of an SBIR proposal entitled Novel Inhibitors for the Treatment of Highly Drug Resistant Chronic Myelogenous Leukemia. The overall goal of this proposal is to test the efficacy of a cla
ss of novel small molecule scaffolds, which… More
Discovery and Development of Anti-Diabetic Drugs.
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Gerard M. Housey – 248-663-7000
Award Amount:
$2,905,013.00
Abstract:
DESCRIPTION (provided by applicant): This is a Resubmission of an NIH Phase II SBIR Renewal Application directed towards developing and optimizing compounds that are capable of stimulating IRS2 foundation for the treatment of Type II diabetes. If successful, such compounds may also be useful for the… More